01419nas a2200481   4500000000100000000000100001000000100002008004100003653004800044653003800092653001100130653001400141653001300155653005400168653002900222653001300251653001700264653004800281653001200329100001200341700001000353700001400363700001500377700001300392700001400405700002100419700002600440700001500466700001300481700002600494700001300520700001700533700001600550700001600566700001400582700001500596700002300611245023800634250001500872300001200887490000700899020003100906       2022                            d10a*COVID-19/epidemiology/prevention & control10aCOVID-19 Vaccines/adverse effects10aHumans10aIncidence10aSyndrome10a*Thrombocytopenia/chemically induced/epidemiology10a*Thrombosis/epidemiology10aCovid-1910apost vaccine10athrombosis-thrombocytopenia syndromes (TTS)10avaccine1 aE. Burn1 aX. Li1 aK. Kostka1 aH. Stewart1 aC. Reich1 aS. Seager1 aT. Duarte-Salles1 aS. Fernandez-Bertolin1 aM. Aragón1 aC. Reyes1 aE. Martinez-Hernandez1 aE. Marti1 aA. Delmestri1 aK. Verhamme1 aP. Rijnbeek1 aS. Horban1 aD. Morales1 aD. Prieto-Alhambra00aBackground rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries  a2022/02/23  a495-5100 v31  a1053-8569 (Print)1053-8569